These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 6318786)

  • 1. beta-Adrenoceptor hypersensitivity after stopping oxprenolol: discrepant findings not attributable to methodology.
    Singh H; Rimmer A; Lewis MJ; Henderson AH
    Br J Clin Pharmacol; 1983 Dec; 16(6):722-4. PubMed ID: 6318786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the duration of action of pindolol and slow release oxprenolol in healthy volunteers.
    Aellig WH
    Eur J Clin Pharmacol; 1978 Nov; 14(3):167-9. PubMed ID: 729611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adrenergic hypersensitivity after beta-blocker withdrawal.
    Ross PJ; Lewis MJ; Sheridan DJ; Henderson AH
    Br Heart J; 1981 Jun; 45(6):637-42. PubMed ID: 6114739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-dosing plasma concentrations and beta-adrenoceptor blocking effects during repeated once daily dosing with 160 mg sustained-release propranolol (Inderal LA) and 16/260 oxprenolol Oros to healthy volunteers.
    Moppert J; Degen PH; Racine-Poon A
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):197S-201S. PubMed ID: 2988591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the beta-adrenoceptor blocking activity of oxprenolol, slow release oxprenolol and a combined oxprenolol diuretic preparation.
    Kerr MJ; Harron DW; Kinney C; Shanks RG
    Br J Clin Pharmacol; 1981 Dec; 12(6):869-71. PubMed ID: 6122463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of beta-adrenoreceptor hypersensitivity after abrupt withdrawal of long-term therapy with oxprenolol.
    Bolli P; Bühler FR; Raeder EA; Amann FW; Meier M; Rogg H; Burckhardt D
    Circulation; 1981 Dec; 64(6):1130-4. PubMed ID: 6117379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The beta 1- and beta 2-adrenoceptor stimulatory effects of alprenolol, oxprenolol and pindolol: a study in the isolated right atrium and uterus of the rat.
    Abrahamsson T
    Br J Pharmacol; 1986 Apr; 87(4):657-64. PubMed ID: 2871880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multiple dose comparative study of the pharmacodynamic and pharmacokinetic behaviour of polymer-matrix and Oros dosage forms of oxprenolol in healthy volunteers.
    Woods KL; Jack DB; Kendall MJ; Halsey A; O'Donnell ML; Warrington SJ; John VA
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):177S-184S. PubMed ID: 4005120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-dose pharmacokinetic and pharmacodynamic comparison of polymer-matrix (Slow Trasicor) and Oros dosage forms of oxprenolol in healthy volunteers.
    Bennett PN; Bennett J; Bradbrook I; Francis J; John VA; Rogers H; Turner P; Warrington SJ
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):171S-175S. PubMed ID: 4005119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors relating to the beta blocker withdrawal syndrome.
    Henderson A; Sheridan D; Ross J; Lewis M
    Ann Acad Med Singap; 1981 Oct; 10(4 Suppl):25-8. PubMed ID: 6124208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade.
    McDevitt DG; Brown HC; Carruthers SG; Shanks RG
    Clin Pharmacol Ther; 1977 May; 21(5):556-66. PubMed ID: 15753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of slow release with conventional oxprenolol: plasma concentrations and clinical effects.
    West MJ; Kendall MJ; Mitchard M; Faragher EB
    Br J Clin Pharmacol; 1976 Jun; 3(3):439-43. PubMed ID: 788749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-2-adrenoceptor-mediated hypokalemia and its abolishment by oxprenolol.
    Jonkers R; Van Boxtel CJ; Oosterhuis B
    Clin Pharmacol Ther; 1987 Dec; 42(6):627-33. PubMed ID: 2826064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of the activity of beta-adrenoceptor antagonists in man.
    Taylor SH; Thadani U; Davidson C; singleton W; Myint S
    Int J Clin Pharmacol Biopharm; 1975 Jul; 12(1-2):305-6. PubMed ID: 240783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine-induced coronary effects in the dog heart attributed to beta- and alpha-adrenergic mechanisms.
    Rabloczky G; Kékesi V; Mader MR; Juhász-Nagy A
    Arch Int Pharmacodyn Ther; 1988; 293():109-26. PubMed ID: 2844127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concentration-effect relationship of oxprenolol in healthy volunteers: a retrospective analysis.
    Racine-Poon A; Moppert J
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):143S-149S. PubMed ID: 4005116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smoking and catecholamine and c-AMP concentrations in the coronary circulation of man and the effect of oxprenolol.
    Robson RH; Fluck DC
    Eur J Clin Pharmacol; 1977 Oct; 12(2):81-7. PubMed ID: 200436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Speed of onset of pharmacodynamic activity of propranolol, practolol, oxprenolol and metoprolol after intravenous infection in man.
    Lochan R; Silke B; Taylor SH
    Br J Clin Pharmacol; 1981 Nov; 12(5):721-4. PubMed ID: 6120711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absorption and excretion of rapid and slow release oxprenolol and their effects on heart rate and blood pressure during exercise.
    Bobik A; Jennings GL; Korner PI; Ashley P; Jackman G
    Br J Clin Pharmacol; 1979 Jun; 7(6):545-9. PubMed ID: 465276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adrenaline activation of prejunctional beta-adrenoceptors in guinea-pig atria.
    Majewski H; McCulloch MW; Rand MJ; Story DF
    Br J Pharmacol; 1980; 71(2):435-44. PubMed ID: 6258697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.